Literature DB >> 1737332

Interleukin 9 is expressed by primary and cultured Hodgkin and Reed-Sternberg cells.

H J Gruss1, M A Brach, H G Drexler, K J Bross, F Herrmann.   

Abstract

We show by mRNA hybridization analysis and immunostaining using a mouse monoclonal antibody (moAb) to recombinant human interleukin 9 (IL-9) that both primary and cultured Hodgkin and Reed-Sternberg (H-RS) cells produce IL-9 transcripts and protein and express surface binding sites for IL-9. In addition, the growth of H-RS cells obtained from the HDLM-2 line (abundantly producing IL-9 transcripts) was significantly inhibited when anti-IL-9 moAb or an IL-9 antisense oligodeoxyribonucleotide was added to cultures. Excess addition of recombinant human IL-9 relieved the effects of anti-IL-9 moAb on HDLM-2 growth. Growth of H-RS cells of the KM-H2 line, which displays only low amounts of IL-9 detectable upon hybridization of polyadenylic acid-selected RNA only, was not affected by anti-IL-9 moAb. The proliferative capacity of KM-H2 cells in soft agar and liquid suspension cultures was, however, augmented at least 3-fold when cells were exposed to recombinant human IL-9. In conclusion, our results show that IL-9 is expressed by H-RS cells and point to a possible role of this molecule as a growth factor for these cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1737332

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Stimulation of growth of human malignant lymphoma and lymphoid leukemia cells in vitro.

Authors:  E S Strobel; K J Bross; R Mertelsmann; F Herrmann
Journal:  Ann Hematol       Date:  1992-02       Impact factor: 3.673

2.  14-3-3zeta interacts with the alpha-chain of human interleukin 9 receptor.

Authors:  D Sliva; M Gu; Y X Zhu; J Chen; S Tsai; X Du; Y C Yang
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

3.  A single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9.

Authors:  J B Demoulin; C Uyttenhove; E Van Roost; B DeLestré; D Donckers; J Van Snick; J C Renauld
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

4.  Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells.

Authors:  Donatella Aldinucci; Dalisa Poletto; Annunziata Gloghini; Paola Nanni; Massimo Degan; Tiziana Perin; Paola Ceolin; Francesca Maria Rossi; Valter Gattei; Antonino Carbone; Antonio Pinto
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

5.  A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1).

Authors:  W Pfeifer; E Levi; T Petrogiannis-Haliotis; L Lehmann; Z Wang; M E Kadin
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

6.  MRG1, the product of a melanocyte-specific gene related gene, is a cytokine-inducible transcription factor with transformation activity.

Authors:  H B Sun; Y X Zhu; T Yin; G Sledge; Y C Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

Review 7.  IL-9-producing T cells: potential players in allergy and cancer.

Authors:  Pornpimon Angkasekwinai; Chen Dong
Journal:  Nat Rev Immunol       Date:  2020-08-12       Impact factor: 53.106

8.  Transforming growth factor beta 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease.

Authors:  S R Newcom; L Gu
Journal:  J Clin Pathol       Date:  1995-02       Impact factor: 3.411

Review 9.  Contribution of Epstein⁻Barr Virus Latent Proteins to the Pathogenesis of Classical Hodgkin Lymphoma.

Authors:  Katerina Vrzalikova; Taofik Sunmonu; Gary Reynolds; Paul Murray
Journal:  Pathogens       Date:  2018-06-27

10.  Do TRIB1 and IL-9 Gene Polymorphisms Impact the Development and Manifestation of Pituitary Adenoma?

Authors:  Tomas Mickevicius; Alvita Vilkeviciute; Brigita Glebauskiene; Loresa Kriauciuniene; Rasa Liutkeviciene
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.